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Objective:We hypothesized that clinical outcome of resected early-stage adenocarci-
noma of the lung can be predicted by the expression of a few critically important genes
as measured by quantitative real-time reverse-transcriptase polymerase chain reaction
in formalin-fixed paraffin-embedded primary tumors.
Methods: Twenty-two prognostic genes for the metastatic phenotype were identified
through complementary DNA microarray analysis of 4 cancer cell lines and bioinfor-
matics analysis. Expression levels of a subset of these genes (n5 13) were measured
by real-time time reverse-transcriptase polymerase chain reaction in formalin-fixed
paraffin-embedded primary adenocarcinoma from patients whose disease recurred
within 2 years (n 5 9) and in patients who did not have a recurrence (n 5 11). Re-
ceiver operating characteristic curves were analyzed to establish prognostic values
of single genes. The most informative gene was combined with the remaining genes
to determine whether there was a particular pair(s) that yielded high diagnostic accu-
racy. A small validation study was performed.
Results: Receiver operating characteristic curve analysis of the single genes revealed
that high expression of CK19 was associated with nonrecurrence (area under the
curve 5 0.859, confidence interval 5 0.651–0.970). The CK19/EpCAM2 gene ratio
had the most reproducible prognostic accuracy, followed by the CK19/P-cadherin
ratio. A Kaplan–Meier survival analysis generated from the CK19/EpCAM2 ratio
resulted in highly significant curves as a function of marker positivity (P5 .0007; haz-
ard ratio 5 10.7). Significance declined but was maintained in the validation study.
Conclusions: This preliminary study provides evidence that the CK19/EpCAM2 and/
or CK19/P-cadherin ratio(s) may be a simple and accurate prognostic indicator of clin-
ical outcome in early-stage adenocarcinoma of the lung. If further validation studies
from large patient cohorts confirm the results, adjuvant therapy could be targeted to
this high-risk group.
D
espite surgical resection, patients with pathologic stage I non–small cell lung
cancer (NSCLC) will have an approximately 30% to 40% incidence of recur-
rence and those with stage II a 45% to 60% recurrence rate.1 At present, the
standard of care is to administer postoperative adjuvant chemotherapy to those
patients with stage II NSCLC.2,3 Although there was initial enthusiasm for adminis-
tering adjuvant therapy to patients with resected stage IB NSCLC, recent data do not
support this practice.3-5 However, subsets of patients with stage I disease could poten-
tially benefit from further treatment to prevent recurrence; likewise, a method to
predict which patients with stage II disease could avoid the unnecessary toxicity of
chemotherapy would be helpful.
The development of metastatic disease is the most common cause of death among
patients with NSCLC and results from dissemination of malignant cells. It is now
recognized that the ability of cells to gain metastatic potential is an intrinsic property
of the primary tumor, which is substantiated by the high correlations between clinical
outcome and gene expression profiles of a variety of primary tumors.6,7 The ability to
predict clinical outcome on the basis of analysis of primary tumors would allow
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Ct 5 cycle of threshold
NSCLC 5 non–small cell lung cancer
RT-PCR 5 reverse-transcription polymerase
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patients with cancer to be treated more effectively. However,
the problem with many of these expression studies is that
they require measurements of large sets of predictive genes
using a platform (complementary DNA [cDNA] microarray
analysis) that is not well suited to clinical application.
In this pilot study, we hypothesized that clinical outcome
of patients with resected early-stage adenocarcinoma of the
lung could be predicted by the expression of relatively few,
but critically important, genes measured by quantitative
real-time reverse-transcription polymerase chain reaction
(RT-PCR) in formalin-fixed paraffin-embedded primary
tumors. Specifically, we hypothesized that there exists
a ‘‘good gene’’ and a ‘‘bad gene’’ such that the ratio of the
two is a strong prognostic indicator of clinical outcome.
Materials and Methods
Identification of 15 Highly Expressed Genes in
NSCLC Cell Lines
Expression levels of 22,283 gene transcripts were determined on ol-
igonucleotide microarrays using RNA prepared from 4 NSCLC cell628 The Journal of Thoracic and Cardiovascular Surgery c Marlines (CRL 5807 [bronchoalveolar carcinoma], CRL 5876 [adeno-
carcinoma derived from metastatic lymph node], A549 [adenocarci-
noma], and HTB 177 (large cell carcinoma]), as well as from a pool
of 4 normal cervical lymph nodes. Eight micrograms of total RNA
per sample were used. First- and second-strand cDNA synthesis,
double-stranded cDNA cleanup, biotin-labeled complementary
RNA (cRNA) synthesis, cleanup, and fragmentation were
performed according to protocols in the Affymetrix GeneChip Ex-
pression Analysis technical manual (Affymetrix, Santa Clara, Calif).
Microarray analysis was performed by the DNA Microarray and
Bioinformatics Core Facility at the Medical University of South
Carolina using U133 A GeneChips (Affymetrix). Fluorescent im-
ages of hybridized microarrays were obtained by an HP GeneArray
scanner (Affymetrix). For normalization, the microarray office suite
was used such that all fluorescence valuesweremultiplied by a factor
that resulted in a mean fluorescent score for all genes equal to 150.
Data for normal lymph nodes were obtained from a previous study.8
All microarray results were imported into a single Microsoft Excel
file. The first algorithm in the selection of highly expressed genes
involved elimination of genes from NSCLC cell lines that were
expressed in normal lymph nodes (n 5 11,326; 50.8% of total
[22,283]). Of the remaining 10,957 genes, those that were detected
in at least 2 NSCLC cell lines were first selected (n5 1731; 7.7% of
total). After this round, genes whose mean fluorescence in all cell
lines was greater than 500 were selected (n 5 91; 0.41% of total).
The final group of 91 genes was sorted according to mean cell
line fluorescence/mean fluorescence of normal lymph nodes, and
the 15 top genes were selected (Table 1).
Bioinformatics Analysis to Identify Potentially
Prognostic Genes in NSCLC
Of the 15 most highly expressed genes identified by cDNA micro-
analysis, it was hypothesized that some were also expressed in other
cancers, whereas some genes were specific for NSCLC. To identifyTABLE 1. Top 15 most highly overexpressed genes in lung cancer cell lines
Gene description Affymetrix results*
1 2 3 4
Rank Gene Acc. No. A549 HTB177 CRL5807 CRL5876 Ratioy
1 AGR2 NM_006408 2124 2053 3082 38 960
2 S100P NM_005980 242 2522 2673 4819 754
3 CK19 NM_002276 27 935 1995 810 589
4 NQO1 NM_000903 1375 1858 982 315 404
5 MET NM_000245 1420 790 2429 378 348
6 MAGE-A6 NM_005363 73 37 3004 4475 311
7 XAGE-1 NM_020411 471 2 2322 3 250
8 KRTHB1 NM_002281 2822 31 221 3 208
9 MAGE-A3 NM_005362 116 29 4055 5107 178
10 MAP7 NM_003980 455 466 381 930 116
11 AKR1B10 NM_020299 11662 10603 17 75 101
12 CK7 related NM_005556 537 21 1319 463 96
13 EpCAM2 NM_002353 2 3 8146 2342 94
14 EpCAM1 NM_002354 278 15 4430 3244 91
15 P-cadherin NM_001793 2 3 1319 1274 87
*Normalized fluorescent values obtained from Affymetrix U133A array data for the indicated cell line. yRatio of mean NSCLC cell line data to mean of normal
lymph node.ch 2008
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online Comparative Genome Anatomy Project (CGAP) National
Cancer Institute 60-gene expression database (URL 5 http://cgap.
nci.nih.gov) using all 15 genes. The output of a given query consists
of a list of 10 genes whose expression levels are most highly corre-
lated with the query sequence. Using the output of each gene, we
constructed a correlation map such that the appearance of a gene
on the map required (1) direct contact with one of the 15 highly ex-
pressed genes, (2) contacts with at least 2 genes, (3) that the corre-
lation coefficient of any 2 genes must have a P value , 8 3 1026,
(4) that the relevant genemust be overexpressed in the CGAP SAGE
data set in at least two cancers (with respect to normal tissue), and (5)
that expression of the relevant gene must be at least 16 to 31 tags/
200,000 sequenced tags in at least one cancer tissue. Genes identi-
fied from the first set of queries were used as query in a reiterative
round of interrogation (data mining).
The correlation map obtained by this bioinformatics data mining
approach contained a total of 22 genes (Figure 1). Seven of the 22
genes (AGR2, Map7, S100P, CK19, EpCAM1, EpCAM2, and P-
cadherin) were derived from the list of 15 most highly expressed
genes and are referred to as the primary prognostic genes (under-
lined in Figure 1). The remaining 15 genes identified from this bio-
informatics approach are referred to as the secondary prognostic
genes (italicized in Figure 1).
Identification of Genes of Prognostic Value in Patients
With Early-stage NSCLC Adenocarcinoma
To determine whether the genes described above had potential
prognostic value, we measured the expression levels by real-time
RT-PCR in paraffin-embedded formalin-fixed primary tumors of pa-
tients whose adenocarcinoma recurred within 2 years (poor outcome
group A; n 5 9) and of patients who survived disease-free longer
than 4 years (good outcome group B; n5 11). Group A patients in-
cluded 2 with stage IA, 2 stage IB, and 5 stage IIB disease. Group B
patients included 5 with stage IA, 3 stage IB, and 3 stage IIB disease.
Genes analyzed included the 7 primary prognostic genes, 6 second-The Journal of Thorary prognostic genes (Sprint 2, Esx, CEA6, Ma12, GPX2, E-cad-
herin), as well as mPAR, a gene whose expression has previously
been shown to be associated with multiple cancers. The laboratory
investigators were initially blinded to the clinical outcome. The
study was approved by the Medical University of South Carolina
Institutional Review Board.
A small validation study was performed using paraffin sections
from patients with early-stage adenocarcinoma who had an early re-
currence (n5 10) and survived greater than 2 years (n5 12) under-
going resection at the Mayo Clinic, Jacksonville, Florida.
Real-time RT-PCR of formalin-fixed paraffin-embedded sam-
ples was performed according to the method of Sprecht and associ-
ates.9 A 50-mm section was cut from tissue blocks of primary tumor
for messenger RNA extraction. For isolation of RNA, paraffin-
embedded tissue sections were deparaffinized twice with 1 mL of
xylene at 37C or room temperature for 10 minutes. The pellet
was subsequently washed with 1 mL of 100%, 90%, and 70% eth-
anol and air-dried at room temperature for 2 hours. The pellet was
resuspended in 200 mL of RNA lysis buffer (2% lauryl sulfate, 10
mmol/L Tris-HCl [pH 8.0], and 0.1 mmol/L ethylenediaminetetra-
acetic acid) and 100 mg of proteinase K and incubated at 60C for
16 hours. RNA was extracted by 1 mL of phenol/chloroform (5:1)
solution (Sigma Chemical Company, St Louis, Mo). The aqueous
layer containing RNA was transferred to a new 1.5-mL tube. Phe-
nol/chloroform extraction was done a total of 3 times. RNAwas pre-
cipitated with an equal volume of isopropanol, 0.1 volume of 3 mol/
L sodium acetate, and 100 mg of glycogen at 220C for 16 hours.
After centrifugation at 12,000 rpm for 15 minutes (4C), the RNA
pellet was washed with 70% ethanol and air-dried at room temper-
ature for 2 hours. Finally, the pellet was dissolved in 12 mL of di-
ethyl pyrocarbonate water. cDNA synthesis was performed with
a panel of truncated gene-specific primers. Real-time RT-PCR
was performed on a PE Biosystems Gene Amp 7300 or 7500
Sequence Detection System (PE Biosystems, Foster City, Calif).
With the exception of the SYBR Green I master mix (purchased
from Qiagen, Valencia, Calif), all reaction components wereG
TSFigure 1. Correlation map of cancer-associated
genes. Correlation map of the genes was con-
structed as described in the text. Genes are
positioned in a hypothetical cell to reflect
intracellular, membrane-bound, or extracellular
localization. The thickness of a solid line con-
necting a given gene pair is proportional to
the R2 value of gene expression, which ranges
from 0.91 (P < .0001) for the Spint1/SNC19 pair,
to 0.55 (P < .0001) for the TFF1/S100P pair.acic and Cardiovascular Surgery c Volume 135, Number 3 629
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mL and contained 1X SYBR RT-PCR buffer, 3 mmol/L MgCl2,
0.2 mmol/L each of deoxyadenosine triphosphate, deoxycytosine
triphosphate, deoxyguanosine triphosphate, 0.4 mmol/L deoxyuri-
dine triphosphate, 0.1 U UngErase enzyme, 0.25 U AmpliTaq
Gold, 0.35 mL cDNA template, and 50 nmol/L of oligonucleotide
primer. Initial steps of RT-PCR were 2 minutes at 50C for UngEr-
ase activation, followed by a 10-minute hold at 95C. Cycles (n 5
40) consisted of a 15-second melt at 95C followed by a 1-minute
annealing/extension at 60C. The final step was a 60C intubation
for 1 minute. All reactions were performed in triplicate. Threshold
for cycle of threshold (Ct) analysis of all samples was set at 0.5 rel-
ative fluorescence units.
Gene expression values were quantified as DCt values, which
were obtained by subtracting the Ct value of an internal reference
control gene (b2-microglobulin, B2M) from the gene of interest.
Ct values are inversely proportional to gene expression levels and
are based on log2 scale.
The results were internally validated by repeating the real-time
RT-PCR process using a new section cut from tissue blocks of the
primary tumor. Variability of tumor quantity on the sections was
minimized by hematoxylin and eosin comparison performed by
a pathologist. A cross-validation procedure was used to determine
whether the results were sensitive to the samples included. A
leave-one-out procedure was used whereby each sample was sys-
temically removed and the data reanalyzed.
Statistical Analysis
To assess for prognostic accuracy, we analyzed receiver operating
characteristic curves on the individual genes normalized to B2M
(Med Calc Software, Mariakerke, Belgium). Prognostic gene com-
binations were tested by subtracting DCt values generated by RT-
PCR analysis. Subtraction of DCt values (DDCt) is equivalent to
the log of the ratio of values. In the text, the DCtgene A 2 DCtgene
B calculation is abbreviated as a gene expression ratio. The value
of the 2-gene prognostic assay was further assessed by Kaplan–
Meier survival analysis.
Results
A primary tumor’s ability to metastasize requires many ge-
netic events. In this study, we hypothesized that there are
relatively few genes that may be critical to the metastatic
phenotype, such that high expression of a gene that portends
nonrecurrence coupled with the low expression of a gene crit-
ical to metastasis would be useful to predict clinical outcome
in adenocarcinoma of the lung.
The correlation map illustrated in Figure 1 resulted from
a unique bioinformatics analysis that led to a set of genes
that had specific structured connections based on a query of
15 genes overexpressed in 4 lung cancer cell lines. Of the
22 identified genes, 7 were in the original query set and
were labeled primary prognostic genes. These genes com-
bined with 6 of the most frequently expressed remaining 16
secondary genes constituted the study’s test gene set in
patients with adenocarcinoma of the lung. This unique
approach is somewhat similar to the description of expression
profiles in different tumors in terms of behavior modules, sets630 The Journal of Thoracic and Cardiovascular Surgery c Maof genes that are in concert to carry out a specific function.10
In fact, many of the genes in this study test set were contained
in one of the modules (module 180) described by Segal and
colleagues.10
Area under the curve (AUC) values for the primary and
secondary genes are shown in Table 2. Receiver operating
characteristic curve analysis of the individual genes revealed
that high expression of CK19 was associated with nonrecur-
rence ($4 years) (AUC 5 0.859; 95% confidence interval
[CI] 5 0.651–0.970); whereas high expression of EpCAM2
was associated with disease recurrence within 2 years
(AUC 5 0.606; 95% CI 5 0.366–0.813).
To determine whether the prognostic accuracy of CK19
could be improved by combining it with another gene whose
overexpression might be necessary for the metastatic pheno-
type and therefore low expression be favorable, we sub-
tracted the mean DCt values of individual genes as
determined by real-time RT-PCR analysis from DCtCK19.
For all potential CK19/gene X combinations, the ratio of
CK19/EpCAM2 yielded the highest prognostic accuracy as
determined by AUC measurements (Table 3). This observa-
tion provided evidence that EpCAM2 is a ‘‘bad’’ gene. The
CK19/EpCAM2 expression ratio, which was derived from
the mean of two experiments, also performed well when
data were analyzed from individual experiments. In the first
and second experiments, the prognostic accuracy of the
CK19/EpCAM2 expression ratio as determined by AUC
analysis was 0.91 (95% CI 5 0.69–0.99) and 0.84 (95%
CI 5 0.56–0.97), respectively (data not shown). Of further
note is the observation that among the 12 patients with stage
I adenocarcinoma, the prognostic accuracy of the CK19/
EpCAM2 expression ratio was 92% (11/12).
TABLE 2. Recurrence analysis of pilot study using single
markers paired with the internal B2M reference control
gene
Recurrence analysis
Gene AUC 95% CI
CK19 0.859 0.631–0.970
EpCAM2 0.606 0.366–0.813
AGR2 0.596 0.357–0.805
Esx 0.566 0.329–0.782
GPX2 0.556 0.320–0.773
CEA6 0.545 0.312–0.765
E-cadherin 0.545 0.312–0.765
EpCAM1 0.535 0.303–0.757
SPINT2 0.530 0.298–0.753
S100P 0.525 0.294–0.749
MAL2 0.515 0.285–0.740
P-cadherin 0.510 0.281–0.736
Map7 0.500 0.272–0.728
UPAR 0.470 0.247–0.702
AUC, Area under the curve; CI, confidence interval.rch 2008
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ferences in inferences. For CK19 alone, the range of AUCs
found in the cross-validation analyses was (0.87 to 0.92)
whereas the AUC when all samples were included was
0.86. Analogous results were found when CK19 was com-
bined with EpCAM2.
To further assess the value of CK19 unpaired and paired
with EpCAM2, we performed a Kaplan–Meier survival anal-
ysis using data generated from single marker and CK19/gene
X analyses. For the single CK19 marker, aDCt cutoff of 11.4
was used, which separated the 20 patients into high (DCt ,
11.4; n 5 13) and low (DCt . 11.4; n 5 7) expressing
tumors. A log–ranked test indicated that the two curves
generated as a function of marker positivity were different
at a P value of .0021 with a hazard ratio of 6.2 (Figure 2,
TABLE 3. Recurrence and survival analysis of pilot study
based on CK19/gene X ratios
Recurrence analysis*
Kaplan–Meier
survival analysisy
GeneX AUC 95% CI P value HR
EpCAM2 0.879 0.656–0.978 .0001 10.7
P-cadherin 0.874 0.650–0.976 .0003 8.13
MAL2 0.869 0.643–0.974 .0004 9.24
Esx 0.742 0.501–0.908 .0008 6.62
Map7 0.889 0.668–0.981 .0013 6.24
UPAR 0.843 0.613–0.963 .0013 6.24
E-cadherin 0.818 0.584–0.951 .0013 6.25
AGR2 0.859 0.631–0.970 .0098 4.69
GPX2 0.722 0.480–0.895 .0184 5.12
SPINT2 0.848 0.619–0.965 .0207 7.78
EpCAM1 0.798 0.561–0.940 .0207 7.78
S100P 0.732 0.490–0.901 .0275 4.08
CEA6 0.732 0.490–0.901 .0729 3.10
AUC, Area under the curve; CI, confidence interval; HR, hazard ratio. *AUC
based on continuous representation of gene expression values. yHazard ra-
tios based on binary analysis of best thresholds of outcome discrimination.The Journal of ThoA). For the CK19/EpCAM2 ratio, a DDCt cutoff of 7.2 was
used, which separated the 20 patients into high (DDCt #
7.2; n 5 13) and low (DDCt . 7.2; n 5 7) groups that
correlated with survival. A log–ranked test indicated that
the two curves generated as a function of marker positivity
were different at a P value of .0001 with an associated hazard
ratio of 10.7 (Figure 2, B). Kaplan–Meier survival analysis of
other CK19/gene X pairs is shown in Table 3. The gene pair
that yielded the second most highly significant curves was
CK19/P-cadherin, with an associated hazard ratio of 8.1.
To determine assay reliability, we applied the 2-gene test to
a set of patients (n5 22) who were treated at theMayo Clinic,
Jacksonville, Florida. Twelve patients survived longer than
2 years, whereas 10 patients had recurrence within 2 years.
All patients in this data set died by 65 months. We observed
that the hazard ratio of CK19/EpCAM2 expression pair
decreased to 4.5 but remained significant (P 5 .007). The
CK19/P-cadherin expression ratio also clearly identified
patients with longer survival (hazard ratio5 3.24;P5 .0029).
Discussion
Unfortunately, a large number of patients with resected early-
stage lung cancer will have a recurrence within 2 to 3 years.
The ability to predict those patients at high risk for recurrence
could help direct the possible addition of therapy to improve
survival and, vice versa, avoid the toxicity for those at low
risk. Many molecular markers that predict patient survival
independent of TNM status have been reported.11 Tools
used to predict recurrence have included immunohistochem-
ical analysis,12 cDNA microarray profiling,13-17 real-time
RT-PCR,6,18-20 and most recently, proteomics.21 Many of
the methods have been costly, not readily available to the
average surgeon, required frozen tissue specimens, and
have therefore been difficult to translate from the research
laboratory to the clinical arena.
In the present study, we measured the expression of 14
different test genes and one internal reference control geneG
TSFigure 2. Kaplan–Meier survival analysis. Data
generated from single-marker (A) and CK19/
EpCAM2 (B) analyses. HR, Hazard ratio.racic and Cardiovascular Surgery c Volume 135, Number 3 631
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NSCLC. Using the B2M gene as an internal reference, we
observed that high expression of CK19 was correlated with
good clinical outcome (no disease recurrence), whereas
high expression of EpCAM2 was correlated with poor clini-
cal outcome (disease recurrence within 2 years). Of all possi-
ble 2-gene combinations (n5 105), we further observed that
the ratio of CK19/EpCAM2 had the highest accuracy for pre-
dicting disease recurrence. The concept of using a 2-gene
ratio was previously applied to NSCLC by Gordon and
coworkers,19,22 who identified S100P as 1 of 7 prognostic
markers. It should be noted that in the Mayo data set, the
marker combination of CK19/S100P yielded results similar
to CK19/P-cadherin (data not shown). However, the current
study is the first to analyze the expression of genes in paraffin
samples. In colon cancer, high expression of EpCAM2 (also
known as TROP2) has been shown to be associated with
a higher frequency of liver metastasis (P 5 .005) and more
cancer-related deaths (P 5 .046),23 a finding that further
supports the concept that for early-stage NSCLC, EpCAM2
is a ‘‘bad gene.’’
The gene pair with the second highest prognostic accuracy
for disease recurrence was CK19/P-cadherin. Previous stud-
ies have shown that expression levels of P-cadherin in pri-
mary tumors correlate with tumor grade in ovarian cancer24
and metastases to the lung in thyroid cancer.25 Further, over-
expression of P-cadherin in vitro results in increased cell
motility in pancreatic cancer,26 a necessary requirement for
establishment of distant metastases. Taken together, these
results provide evidence that P-cadherin may also serve as
a candidate ‘‘bad gene’’ in NSCLC. Regarding CK19, anti-
bodies to the protein encoded by this gene (and/or a combina-
tion of other cytokeratin genes) have been used for the
detection of circulating tumor cells in breast, lung, colon,
and other cancers.27,28 In the current study, we suspect that
CK19 expression levels serve as a reliable indicator of the
epithelial content of the primary tumor.
Although there was a recent report of the use of real-time
RT-PCR for prognosis of patients with early-stage NSCLC,
the current study differs significantly from the approach
taken by Chen and colleagues.20 In this report, patient prog-
nosis was based on a simple calculation of a 2-gene ratio, an
approach that contains only one ‘‘decision node.’’ In the
study of Chen and associates, a 5-gene marker panel was
used that required a relatively high number of decision nodes
(n 5 19). An algorithm that uses such a high number of
decision nodes for a low number of genes is less likely to
be clinically applicable because of its cumbersome nature.
In contrast, the microarray study of Potti and coworkers6
required only 5 decision nodes, even though 289 genes
were involved.
There are several advantages to the technique used in this
preliminary study. It is a simple 2-genemodel and uses a tech-
nology that is relatively inexpensive and is quickly per-632 The Journal of Thoracic and Cardiovascular Surgery c Maformed once RNA is extracted. Paraffin-embedded tumor
tissue can be screened and an appropriate slide(s) could be
sent to a reference laboratory. The technique is amenable to
small tissue samples, which may be important if preoperative
biopsy directs neoadjuvant therapy.
Several limitations of this pilot analysis need to be
acknowledged. First, given the small numbers used for the
preliminary study, external verification must be performed
on a larger data set before definitive statements are made con-
cerning its application as a prognostic tool. Second, given the
number of putative genes that could display either a direct or
inverse relationship between expression and prognosis, it is
possible that another gene ratio or a combination of two ratio
sets will be more informative as patients are added. Correla-
tive experiments looking at protein levels in tumor issues
should be a future goal.
In summary, a simple 2-gene molecular model has been
developed to predict recurrence in patients having resection
of early-stage adenocarcinoma of the lung. The model will
require further validation and refinement. It is hoped that in
the future a relatively easy, cost-effective, clinically relevant
molecular model will be used to individualize therapy in
early-stage NSCLC.
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Discussion
Dr Virginia R. Litle (New York, NY).Dr Reed, you have addressed
a very important clinical question: Which patients with early-stage
lung cancer may benefit from adjuvant therapy because they are at
higher risk of recurrent disease. You have tried to keep it simple
and straightforward and emphasize that. However, I have a few
questions about the research design.
In this study you compared gene expression in the tumors versus
the normal tissue. Often this may be better suited to identifyingThe Journal of Thordiagnostic markers rather than prognostic markers. You compared
gene expression in the tumor cell lines with that in normal lymph
nodes. This approach would typically identify potential markers
for detection of lymph node metastases. It is not clear to me why
this would identify markers that may be predictive of prognosis
for poor outcome. Maybe you could clarify the logic of this
approach.
Following up on that, in your table for recurrence analysis of sin-
gle markers, the AUCwas greater than 0.6 for CK19 only. For all the
other markers, it was less than 0.6. How do we know identification
of these markers might only be occurring by chance?
Dr Reed. The idea here was to try to simplify the process, as you
noted, and the study actually started by looking at the ability to pre-
dict recurrence on lymph nodes gathered by very minimally invasive
ways. After a series of studies, it became apparent that if the hypoth-
esis was to predict the metastatic phenotype, we should be looking at
the primary tumor itself rather than looking at lymph nodes.Wewent
back to look at the primary tumors and found that correlated much
better with the metastatic phenotype than looking at normal tissue.
Therefore, through a series of algorithms and using the database,
we then looked at those genes that were connected with each other
in metastatic disease. It turns out that there have been other studies
to verify that it looks like EpCAM2, particularly, is a molecule that
may be a causal link to metastases. I think your question concerns
what is diagnostic and what is prognostic, and our study is really try-
ing to identify those patients whom we could test up front through
looking at their primary tumors to determine the likelihood of recur-
rence. Thus our focus has been really prognostic, not diagnostic. That
does not mean the efforts that we have used and the type of things we
are doing could not be potentially used in a diagnostic manner. That
is actually thewaywe started out, trying to look at early diagnosis and
prognosis of metastasis with the lymph nodes gathered through min-
imally invasive approaches, and, frankly, it did not pan out.
Dr Litle. Are you confident that you will be able to validate this
on a separate sample set?
Dr Reed. That is a good question. We already have validated it
on a separate set of patients who were supplied to us by our associ-
ates at Mayo–Jacksonville. In one of the conclusions, I was careful
to say that the CK19/EpCAM2 ratio may be a prognostic indicator.
The other ratio that may be very useful is the CK19/P/cadherin ratio.
I did not have time to look at my cancer-associated map, which is
pretty complex. However, if we look at the connection of these
genes, it appears that there is a transcription gene at the center of
this map that may be a molecular target for a drug, and that is our
ultimate goal.
Dr Litle.What do you think is the biological or functional ratio-
nale behind CK19 being involved as a poor prognostic factor?
Dr Reed. Well, CK19 is not a poor prognosticator. It is a good
prognosticator.
Dr Litle. Excuse me, a good prognostic factor.
Dr Reed. It is a cytoskeletal protein. I do not know the answer to
that. It obviously remains intact, and so when we put it up with the
other ratios of the other genes, it turned out to be very prognostic.
I cannot answer that question with any great expertise.
Dr Raphael Bueno (Boston, Mass). I am delighted that you are
presenting these results. We published this concept in mesothelioma
and lung cancer in 2002 in a cover article of Cancer Research, val-
idated it in mesothelioma in the Journal of the National Canceracic and Cardiovascular Surgery c Volume 135, Number 3 633
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G
TSInstitute, did the same thing in adenocarcinoma of the lung in terms
of early prognosis in 2004, and published on it extensively again.
I am pleased that you have provided us with external validation of
our work.
I can answer some of the questions that Dr Litle asked, as we
have been studying this method using National Institutes of Health
grants. This method provides for a signal-to-noise ratio, and that is
why it is so powerful. In addition, the genes used here may have ab-
solutely no biological meaning. These genes’ overexpression may
result from a downstream event that may be mechanistically mean-
ingful or not. One of the prognostic genes in poor-outcome adeno-
carcinomas that we have reported is the glucose transporter that lets
the F-deoxyglucose get into the cells for ‘‘lighting up’’ positron
emission tomographic scans, for example, which is consistent
with other data about that glucose transporter gene expression.
We also found that it is best at the initial comparative set to identify
the genes and then refine them in the training set. As we have been
doing this in lung cancer, mesothelioma, prostate cancer, and other
cancers, we found that actually a combination of two or three ratios
gives us a much better specificity and sensitivity.
I hope that you continue to work on it and be successful. I would
like to declare that I do have a slight conflict of interest as my insti-
tution has a patent pending on this technology.
Dr David R. Jones (Charlottesville, Va). You looked at overex-
pressed genes. As you know, there are many genes that in fact are634 The Journal of Thoracic and Cardiovascular Surgery c Masuppressors of metastasis and there is a loss of these genes. Have
you thought about going back and looking at maybe the top 15 genes
that are underexpressed to determine whether there is a difference?
Second, what is the biology of EpCAM2, or how does its
signaling really work, for those of us who are not as familiar with
that?
Dr Reed. The reason we looked at overexpressed genes was be-
cause of the RT-PCR that we used. We believed that if we looked at
overexpressed genes, the sensitivity would be much higher. That is
a very good point, but that was the reason that we looked at overex-
pressed genes.
EpCAM2 (also know as TROP2) is a molecule that is believed to
be involved in hemotypic intracellular adhesion of epithelial cells,
signal transduction. There has been a very recent presentation at
the American Association of Cancer Research meeting to show
that EpCAM2 particularly is overexpressed in a large number of me-
tastases, from colon, stomach, breast, and ovary tumors and may
very well be a novel widespread stimulator of cancer growth. There
is a lot of information actually that EpCAM2 is an important gene
for metastasis.
Dr Jack A. Roth (Houston, Tex). It is a very nice study. Have
you looked at the protein levels with immunohistochemistry? Do
they correlate with your RNA levels?
Dr Reed. The team at Mayo Clinic–Jacksonville is doing that
now. We have given them our correlative slides to do that study.rch 2008
